Objective: HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) can progress slowly or rapidly even though a set of symptoms such as spastic paraparesis with pathological reflexes and sweating loss of the lower extremities are commonly observed in patients. Although most of the patients are thought to be infected to HTLV-1 from their mothers by breast feeding, symptoms of HAM/TSP typically manifest in patients later in life (50-60 years old in age) and also with a higher prevalence of women to men at a ratio 
Abstract
Objective: HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) can progress slowly or rapidly even though a set of symptoms such as spastic paraparesis with pathological reflexes and sweating loss of the lower extremities are commonly observed in patients. Although most of the patients are thought to be infected to HTLV-1 from their mothers by breast feeding, symptoms of HAM/TSP typically manifest in patients later in life (50-60 years old in age) and also with a higher prevalence of women to men at a ratio Disease phenotypes of HAM/TSP can be heterogeneous even though a set of symptoms such as spastic paraparesis with pathological reflexes, urinary disturbance, mild sensory disturbance and sweating loss of the lower extremities are commonly observed in patients.
Based on longitudinal clinical observations and follow-ups, HAM/TSP can be characterized as rapidly or slowly progressive types. Approximately 30% of HAM/TSP patients exhibit rapid progression of disease, meaning the time from onset of disease to inability to walk is less than 2 years. Contrasting the rapid disease phenotype is the slow, protracted form of disease which can take as long as 15 years to progress [8] . Factors that may influence how fast an individual's disease may progress are yet to be identified, while several risk factors and non-HLA gene polymorphisms are closely associated with the development of HAM/TSP [9] . The major route of HTLV-1 infection is from mothers by a breastfeeding.
Symptoms of HAM/TSP, however, typically manifest in patients later in life (50-60 years old in age) and also with a higher prevalence of women to men at a ratio of approximately 3:1 [8, [10] [11] [12] . The reasons for these characteristics of this unique infectious disease also remain unknown. A complex multi-step pathogenic process leading to disease manifestation may in part explain the long latency in disease development. Nevertheless, few studies have to-date attempted to address the elevated female prevalence in HAM/TSP.
We designed a retrospective comparative study of 150 sequential patients admitted to our hospital in the last 12 years and tried to identify disease determinants or biomarkers that may be of value to clinicians when assessing HTLV-1 related disease subtypes.
Subjects and Methods
We reviewed the medical records of 150 consecutive patients with HAM/TSP who were admitted to Kagoshima University Hospital from January 2002 to June 2014. HAM/TSP was diagnosed according to the World Health Organization diagnostic criteria [13] . Clinical information was obtained from medical records of patient attendance at our hospital.
Clinical variables included sex, age, age at onset, an initial symptom, a score of a neurological disability and blood and cerebrospinal fluid (CSF) tests. Neurological disability was assessed using Osame Motor Disability Score (OMDS) as reported previously. The score were defined as follows: 0, no disability; 1, walking slow; 2, a little trouble when walking; 3, unable to run; 4, needs guardrail while going up the stairs; 5,
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JNS -revised text 5 needs one hand support while walking; 6, needs two hands support while walking (more than 10 meters); and 7, needs two hands support while walking (less than 10 meters); 8, needs two hands support while walking (less than 5 meters); 9, unable to walk but can crawl; 10, unable to crawl but can move; 11, unable to move but can roll over on the bed; 12 unable to roll over; 13, unable to flex toes [14] .
The subgroup of the patients with rapid progression was defined by deterioration of motor disability by more than 3 grades within 2 years. This definition was applied to disease onset and any time point in the disease course. A routine test for blood and cerebrospinal fluid of the patients were evaluated. Anti-HTLV-1 antibodies in serum and CSF were detected using enzyme-linked immunosorbent assay and particle agglutination methods (Fijirebio Inc, Tokyo, Japan). HTLV-1 PVL in peripheral blood mononuclear cells (PBMCs) was assayed by quantitative PCR using the ABI PRISM 7700TM sequence detection system as reported previously [15] . We analyzed these laboratory data and the clinical parameters including the sex, age of disease onset, initial symptom and disease course.
HTLV-1 PVL of asymptomatic carriers was measured with the blood samples from 89 individuals after obtaining informed consent.
Statistical analysis
Data were analyzed using SPSS-20 (SPSS, Chicago, Illinois). Statistical analyses were performed using parametric (t test) and non-parametric tests (Mann-Whitney test) for continuous variables and χ 2 (Pearsonχ 2 test/Fisher exact test) for categorical variables.
Differences were considered significant when p < 0.05.
Results

Clinical and laboratory data of the patients with HAM/TSP
We made a bar chart representing a frequency distribution of age of disease onset with 150 consequent patients who had been diagnosed with HAM/TSP from 2002 and 2014. The probability of developing symptoms at any given age was in accordance with a skewed normal distribution pattern (Figure 1a ). Between the 5th and 7th decades, was when the chances of developing HAM/TSP disease increase. The averages of age, age of onset, and duration of illness of all the patients were 61.5 years old, 50.6 years old and 10.9 years, respectively ( Table 1) . On the laboratory data, the average of anti-HTLV-1 antibody titer (PA) in serum and cerebral spinal fluid (CSF) of all the patients were 29,141x and 594.2x, respectively. Average of HTLV-1 proviral load (PVL) was 9.42% in PBMCs. There is no significant difference in these parameters other than the level of protein in the CSF between the sexes. The level of protein in the CSF of the female patients was significantly less than that of the male patients, while there is no difference in a cell count and a level of neopterin between them (Table 1 ). 
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Characteristics of the patients presenting with rapid and slow disease progression
We segregated patients into two groups based on disease phenotypes, and compared the groups ( Table 2 ). The patients presenting with rapid progression were significantly older at onset than those with slow progression (61.5 vs. 46.8 years old, p < 0.001). The time elapse between onset and wheelchair use in daily life was markedly shorter among patients with rapidly progressing disease (1.4 vs. 15.7 years, p < 0.001). Anti-HTLV-1 antibody titer was also significantly higher in the CSF of the patients with rapid progression than in that with slow progression (1,210x vs. 366x, p < 0.001), but the difference in the titer was not found in the serum. Cell counts and the protein level were significantly higher in the CSF of the patients with rapid progression than in that with slow progression (11.1 vs. 3.3 cells, p < 0.001; 54.9 vs. 36.1 mg/dl, p < 0.001, respectively). HTLV-1 PVL was significantly lower in patients with rapid progression than in those with slow progression (408 vs. 1,158 copies / 10 4 PBMCs, p =0.008). The PVL of the patients with rapid progression was slightly higher than that with asymptomatic carriers in our hospital is 366±657 copies.
We wondered if initial presentations were prognostic, and tabulated frequencies of five common symptoms including gait disturbance, urinary and sensory disturbances, constipation and lumbago ( Figure 2 ). Patients were separated into cohorts based on their respective divergent disease courses for further analysis (Figure 2a ). Our result, albeit suggestive, demonstrates that urinary disorders were more often noticed in patients affected with the protracted form of disease, while sensory symptoms were markedly increased in patients with rapid progression.
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Difference in clinical course between the sexes
We compared the clinical features of the female patients with those of male patients to find some association between the sexes and the disease courses. There is no significant difference in OMDS and diseases course between the sexes (Table 3) . We tabulated frequencies of five common symptoms including gait disturbance, urinary and sensory disturbances, constipation and lumbago to find a difference between the sexes. There is no significant difference in the initial symptom between the sexes (Figure 2b) . Lastly, we calculated the ratio of rapid progression in each decade of onset age. The proportion of patients with rapid progression increased with the onset age both in male and female (Figure 3a -c). A C C E P T E D M A N U S C R I P T Figure 3 . Proportion of patients with rapid and slow disease progression by age of onset.
DISCUSSION
Our result showed that the male to female ratio was 1:3 in 150 sequential patients with to the weakness of the lower extremities by aging or sex. However, the measured values of CSF cell count, and protein levels were specifically elevated in patients with rapid disease in the present study. Additionally, HTLV-1 antibody titer in both serum and CSF were evaluated. Only in the CSF was a difference detected between rapid and slow progression.
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Although we also expected the significant elevation of neopterin, the difference did not reach statistical significance. It may be because of a small number of rapidly progressing cases. In addition to small number of samples, we have to take it into consideration the time point of the sample collection. The blood samples were not always collected during progression of the disease. The rapid progression was defined with the past history of the patient in this study. When the level of neopterin was elevated just during the period of disease progression, the difference must be smaller than we expected in our retrospective study. Together, these biomarkers suggest inflammation, cellular and molecular events leading to spinal cord tissue damage in HAM/TSP are indeed virus mediated. The high prevalence of rapid progression in older age is attributed to not only the weakness of the legs by aging but also to some other factors. Concerned he neopterin A previous study on donated blood samples shows that there was no difference in prevalence of HTLV-1 carrier between the sexes until 5th decades and that the prevalence in female become to be higher than that in male after 5th decades in Japan. [19] . The exact reason for the difference in prevalence is not elucidated, A sexual transmission may be partially contributed to the difference. Concerned to blood transfusion, the frequency of blood transfusion before the onset of the disease is significantly high compared with that in the general population [20] . HAM/TSP sometimes occurs in the short period after blood transfusion. The immune response of the host in an infection to HTLV-1 by blood transfusion may be different from that in a mother-to-child infection by breast feeding.
Similarly, the immune response of the host to HTLV-1 in an infection by sexual intercourse in older age may be different from that in a mother-to-child infection. So we hypothesized that some female patients infected by a sexual intercourse shows strong immune response to HTLV-1, resulting in presenting with a rapid progression in elderly female. However, in the present study, we did not find out the difference in onset age, the ratio of rapid progression and the period from onset to wheelchair-use between the sexes. Although we think HTLV-1 can be transmitted by a sexual intercourse, one's gender is not strongly associated with age of onset or diseases course of HAM/TSP in the present study.
Biomarkers that are highly differential and may be of value in supporting disease diagnosis which we identified in this retrospective study are CSF cells, protein level, and HTLV-1 antibody titer. HTLV-1 PVL in PBMC has been demonstrated to strongly correlate with disease severity in a number of previous studies. And its utility as a biomarker to aid in disease prognosis was also suggested by Olindo et al [16, 18, 21] . Unexpectedly, in our study, the patients with rapid disease progression had lower PVL. Because the PVLs were evaluated with the samples at their admission to our hospital, the PBMCs are collected both from the patients before and during rapid progression. We should warrant further investigations to address the accepted hypothesis that disease progression and severity are strictly driven by PVL in PBMC. The reasons for these differing observations are unclear at this point.
Our results suggest that age and virus mediated inflammation are correlated with disease phenotypes while additional factors such as host or HTLV-1 genetics and gender may influence disease susceptibility.
